“용인립카페🎐 〔ØΡＤΑＬⓞ②ⓞㆍㄷΘм〕오피달리기 😴용인립카페🚌용인풀싸롱🏢용인스웨디시🔷용인아로마🏪용인오피🚬용인OP👔”的搜索结果，显示 221-230 项，共有 16358 项

1. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Participants in both Phase 1 and 2 will be selected for treatment with \[177Lu\]Lu FAP 2286 based on \[68Ga\]Ga FAP 2286 imaging for determining tumor FAP ...

3. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... 2 negative (ER+/HER2-) advanced or metastatic breast cancer that has progressed on treatment with everolimus in combination with exemestane or fulvestrant.

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day 1 and ...

6. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   This is a phase 1b/2 study of the safety and efficacy of MLN0128 in combination with exemestane or fulvestrant therapy in women with estrogen receptor positive/ ...

7. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... 2 dose (RP2D) 1.1.2 To evaluate the safety and tolerability of this combination in a dose expansion cohort in patients with uterine serous carcinoma.

8. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The goal of this clinical research study is to learn how often breast cancer recurs (returns after treatment) in the breast in patients who have been ...

9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... 2 negative (ER+/HER2-) advanced or metastatic breast cancer that has progressed on treatment with everolimus in combination with exemestane or fulvestrant.

10. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...